Peptides inhibiting cold-inducible RNA binding protein activity
AssigneeThe Feinstein Institute for Medical Research
InventorPing Wang
Life of this patent
Estimating the term…
Abstract
Disclosed are pharmaceutical compositions comprising a CIRP inhibitor. Methods of treating a subject suffering from an inflammatory condition comprising administering to said subject a CIRP inhibitor are also described herein.
Claims4
A synthetic peptide fragment of Cold-Inducible RNA-Binding Protein (CIRP), selected from the group consisting of:
- a synthetic peptide consisting of the amino acid residue sequence Gly-Arg-Gly-Phe-Ser-Arg-Gly-Gly-Gly-Asp (SEQ ID NO:
- 12), wherein at least one amino acid is a D-amino acid,
- a synthetic peptide consisting of the amino acid residue sequence Gly-Gly-Arg-Gly-Arg-Gly-Arg-Gly-Phe-Ser-Arg-Gly-Gly-Gly-Asp (SEQ ID NO:
- 13), wherein at least one amino acid is a D-amino acid, and
- a synthetic peptide consisting of the amino acid residue sequence Gly-Arg-Gly-Phe-Ser-Arg-Gly-Gly-Gly-Asp-Arg-Gly-Tyr-Gly-Gly (SEQ ID NO:
- 14), wherein at least one amino acid is a D-amino acid,
- or a pharmaceutically acceptable salt thereof;
- and wherein the synthetic peptide fragment improves wound healing in contrast to naturally occurring CIRP.
A synthetic peptide fragment of Cold-Inducible RNA-Binding Protein (CIRP), selected from the group consisting of:
- a synthetic peptide consisting of the amino acid residue sequence Gly-Arg-Gly-Phe-Ser-Arg-Gly-Gly-Gly-Asp (SEQ ID NO:
- 12), wherein each amino acid is a D-amino acid,
- a synthetic peptide consisting of the amino acid residue sequence Gly-Gly-Arg-Gly-Arg-Gly-Arg-Gly-Phe-Ser-Arg-Gly-Gly-Gly-Asp (SEQ ID NO:
- 13), wherein each amino acid is a D-amino acid, and
- a synthetic peptide consisting of the amino acid residue sequence Gly-Arg-Gly-Phe-Ser-Arg-Gly-Gly-Gly-Asp-Arg-Gly-Tyr-Gly-Gly (SEQ ID NO:
- 14), wherein each amino acid is a D-amino acid,
- or a pharmaceutically acceptable salt thereof;
- and wherein the synthetic peptide fragment improves wound healing in contrast to naturally occurring CIRP.
A synthetic peptide fragment of Cold-Inducible RNA-Binding Protein (CIRP), selected from the group consisting of:
- a synthetic peptide consisting of the amino acid residue sequence Gly-Arg-Gly-Phe-Ser-Arg-Gly-Gly-Gly-Asp (SEQ ID NO:
- 12), wherein the amino terminal is acetylated and the carboxy terminal is amidated,
- a synthetic peptide consisting of the amino acid residue sequence Gly-Gly-Arg-Gly-Arg-Gly-Arg-Gly-Phe-Ser-Arg-Gly-Gly-Gly-Asp (SEQ ID NO:
- 13), wherein the amino terminal is acetylated and the carboxy terminal is amidated, and
- a synthetic peptide consisting of the amino acid residue sequence Gly-Arg-Gly-Phe-Ser-Arg-Gly-Gly-Gly-Asp-Arg-Gly-Tyr-Gly-Gly (SEQ ID NO:
- 14), wherein the amino terminal is acetylated and the carboxy terminal is amidated,
- or a pharmaceutically acceptable salt thereof;
- and wherein the synthetic peptide fragment improves wound healing in contrast to naturally occurring CIRP.
A synthetic peptide fragment of Cold-Inducible RNA-Binding Protein (CIRP), selected from the group consisting of:
- a synthetic peptide consisting of the amino acid residue sequence Gly-Arg-Gly-Phe-Ser-Arg-Gly-Gly-Gly-Asp (SEQ ID NO:
- 12), wherein the amino terminal is acetylated or the carboxy terminal is amidated,
- a synthetic peptide consisting of the amino acid residue sequence Gly-Gly-Arg-Gly-Arg-Gly-Arg-Gly-Phe-Ser-Arg-Gly-Gly-Gly-Asp (SEQ ID NO:
- 13), wherein the amino terminal is acetylated or the carboxy terminal is amidated, and
- a synthetic peptide consisting of the amino acid residue sequence Gly-Arg-Gly-Phe-Ser-Arg-Gly-Gly-Gly-Asp-Arg-Gly-Tyr-Gly-Gly (SEQ ID NO:
- 14), wherein the amino terminal is acetylated or the carboxy terminal is amidated,
- or a pharmaceutically acceptable salt thereof;
- and wherein the synthetic peptide fragment improves wound healing in contrast to naturally occurring CIRP.
Dependencies are inferred from the claim text.